AstraZeneca plans to list on NYSE, but will remain in the U.K.

"AstraZeneca laid out plans on Monday to switch to a direct listing of its shares in the United States, as the drugmaker seeks to maximise gains from a booming U.S. stock market, even as it said it was not exiting London. The decision to remain UK-based and listed there will be of some relief to British investors after media reports suggested the Anglo-Swedish drugmaker-London's most valuable company-was considering ditching its UK listing in favour of the U.S."

"AstraZeneca said it would list its shares on the New York Stock Exchange and move away from the current depositary receipts structure, with trading expected on February 2, 2026. Trading in fully listed stocks is generally more liquid than in ADRs, attracting more investors. The company will remain headquartered in the UK and listed in London and Stockholm, with the plan subject to a shareholders' vote on November 3."

"Nearly 22% of AstraZeneca's shareholder base is from North America, its biggest, according to LSEG data, in line with other top UK-based blue-chip companies. Iain Pyle at Aberdeen Group, a shareholder, said the main takeaway from the announcement was AstraZeneca's "re-commitment" to the primary listing in the UK. "From our point of view, (AstraZeneca) remains an attractive investment on a fundamental basis, with a broad pipeline still undervalued by the market - the listing location doesn't alter that view.""

AstraZeneca plans to switch to a direct U.S. listing on the New York Stock Exchange while retaining primary listings in London and Stockholm and keeping its UK headquarters. The company will move away from depositary receipts, aiming for greater liquidity and broader investor access, with trading expected from February 2, 2026. The plan is subject to a shareholder vote on November 3. Nearly 22% of shareholders are based in North America. London-listed shares rose about 1% on the announcement but have underperformed peers and the FTSE 100 year-to-date. Company leadership described the structure as harmonised and committed to the UK.

Read at Fast Company